Abstract
Immune adjuvants, such as ligands for pathogen-associated molecular patterns (PAMPs), have been showing promise in boosting immune responses to tumor associated antigens, and delivering these adjuvants as discrete packages is considered advantageous over delivery in soluble form. Here we describe in detail, methods for independently loading a range of adjuvants into polymer-based biodegradable particles. We also describe the means by which to characterize these particles with respect to adjuvant loading and release kinetics as well as in terms of particle size, shape, and zeta-potential. These adjuvant-loaded particles have the potential to be used in dendritic cell-based uptake experiments performed in vitro or to be used in preclinical cancer vaccine research applications where they can be co-delivered with antigen-loaded particles or some other vaccine component comprising antigenic material.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39(1):38–48
Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3(8):630–641
Ahmed KK, Geary SM, Salem AK (2014) Applying biodegradable particles to enhance cancer vaccine efficacy. Immunol Res 59(1-3):220–228
Eldridge JH et al (1991) Biodegradable microspheres as a vaccine delivery system. Mol Immunol 28(3):287–294
Hamdy S et al (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63(10-11):943–955
Schijns VE, Lavelle EC (2011) Trends in vaccine adjuvants. Expert Rev Vaccines 10(4):539–550
Tefit JN, Serra V (2011) Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev Vaccines 10(8):1207–1220
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216
Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature 449(7164):819–826
Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16–34
Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222(1):357–368
Steinhagen F et al (2011) TLR-based immune adjuvants. Vaccine 29(17):3341–3355
Giannini SL et al (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34):5937–5949
Ammi R et al (2015) Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther 146:120–131
Hafner AM, Corthesy B, Merkle H (2013) Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 65(10):1386–1399
Hemmi H et al (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196–200
Kobold S et al (2014) Modes of action of TLR7 agonists in cancer therapy. Immunotherapy 6(10):1085–1095
Bode C et al (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10(4):499–511
Yan S, Gu W, Xu Z (2013) Re-considering how particle size and other properties of antigen-adjuvant complexes impact on the immune responses. J Colloid Interface Sci 395:1–10
Gutierro I et al (2002) Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21(1-2):67–77
Katare YK, Muthukumaran T, Panda AK (2005) Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 301(1-2):149–160
Rueckert C, Guzman CA (2012) Vaccines: from empirical development to rational design. PLoS Pathog 8(11):e1003001
Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489
Colditz GA et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271(9):698–702
Nabel GJ (2013) Designing tomorrow’s vaccines. N Engl J Med 368(6):551–560
Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3(3):1377–1397
Shaffie KA et al (2010) Effect of polyvinyl alcohol of different molecular weights as protective colloids on the kinetics of the emulsion polymerization of vinyl acetate. J Am Sci 6(10):1202–1212
Foged C et al (2005) Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 298(2):315–322
Sah E, Sah H (2015) Recent trends in preparation of poly(lactide-co-glycolide) nanoparticles by mixing polymeric organic solution with antisolvent. J Nanomater 2015:1–22
Joshi VB, Geary SM, Salem AK (2013) Biodegradable particles as vaccine delivery systems: size matters. AAPS J 15(1):85–94
Hines DJ, Kaplan DL (2013) Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights. Crit Rev Ther Drug Carrier Syst 30(3):257–276
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
de Barros, C.M., Wafa, E.I., Chitphet, K., Ahmed, K., Geary, S.M., Salem, A.K. (2017). Production of Adjuvant-Loaded Biodegradable Particles for Use in Cancer Vaccines. In: Fox, C. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 1494. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6445-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6445-1_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6443-7
Online ISBN: 978-1-4939-6445-1
eBook Packages: Springer Protocols